Yellow fever is an epidemic-prone disease caused by the bite of an infected mosquito that can be prevented by vaccination. Yellow fever is caused by an arbovirus (a virus spread by vectors such as mosquitoes, ticks, or other arthropods) that is spread to humans by infected mosquitoes (Aedes and Haemagogus). These mosquitoes breed in houses, in forests or jungles, or in both habitats. Yellow fever is a high-threat disease with a risk of spreading globally, thereby posing a threat to global health security. The common symptoms of yellow fever include headache, fever, nausea, and vomiting. In severe cases, yellow fever can also affect some organs such as the heart, kidney, and liver.
The global yellow fever treatment market is estimated to be valued at US$ 470.5 million in 2021 and is expected to exhibit a CAGR of 3.7% during the forecast period (2021-2028).
Figure 1.Global Yellow Fever Treatment Market Share (%) in Terms of Value, by Treatment Type, 2021
The increasing prevalence of yellow fever is expected to drive the market growth during the forecast period
The increasing prevalence of yellow fever is expected to drive the market growth of the global yellow fever treatment over the forecast period. For instance, according to an article published in ‘Journal of Medical Virology’, yellow fever affects 84,000 to 170,000 people in Africa each year, with 29,000–60,000 deaths.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 470.5 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 3.7% | 2028 Value Projection: | US$ 607.6 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Sanofi Pasteur SA, Janssen, Pfizer Inc., BIOCRYST PHARMACEUTICALS, INC., Tychan Pte. Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Bayer AG, GlaxoSmithKline plc, Bio-Manguinhos, Institut Pasteur de Dakar, and FSUE Chumakov |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2.Global Yellow Fever Treatment Market Share (%), by Application, 2021
The increasing use of technology such as artificial intelligence is expected to drive the market growth during the forecast period
Advanced technologies and the use of artificial intelligence are expected to drive the global yellow fever treatment market growth during the forecast period. For instance, in September 2021, scientists from the ‘Research Centre of Biotechnology’ of the Russian Academy of Sciences developed a technology and synthesized five of the most promising compounds and investigated their activity using artificial intelligence. The molecules they chose were related to the derivatives of pyrazosulphonamide.
The above research was conducted in cooperation with Collaborations Pharmaceuticals, Inc., a private company specialized in innovative therapeutics for multiple rare and infectious diseases (based in the U.S.). The team used a predictive computer model in combination with several machine learning methods. For model training, they relied on in vitro screening data and information available in existing databases to select and identify the ideal molecule features for the desired activity. By using these computational models, they predicted their bioactivity before testing them in vitro using NIAID resources.
Global Yellow Fever Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 disease has spread to over 100 countries since its outbreak in December 2019. On January 30, 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency.
The COVID-19 pandemic has impacted clinical trials in a significant way. Various trials have been paused, and researchers have been facing a lot of challenges in visiting remote areas and performing the necessary laboratory and other study assessments required for carrying out the trials effectively.
Furthermore, key players operating in the global yellow fever treatment market also faced various challenges due to the COVID-19 pandemic. The major challenges include the supply of raw materials required for manufacturing drugs due to transportation disruption. Moreover, distributors are facing irregular product demand from retailers due to an increase in the number of patients suffering from COVID-19.
Global Yellow Fever Treatment Market: Restraint
The major factors that hinder the growth of the global yellow fever treatment market include limited treatment options and severity associated with taking wrong medications due to misdiagnosis or incorrect self-diagnosis.
Key Players
Major players operating in the global yellow fever treatment market include Sanofi Pasteur SA, Janssen, Pfizer Inc., BIOCRYST PHARMACEUTICALS, INC., Tychan Pte. Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Bayer AG, GlaxoSmithKline plc, Bio-Manguinhos, Institut Pasteur de Dakar, and FSUE Chumakov.
Yellow fever is a serious disease spread by Aedes aegypti mosquitoes, which also transmit dengue and Zika viruses. Mosquitoes normally breed in tropical rainforests, semi-humid environments, and humid environments, as well as around bodies of still water. Increased contact between humans and infected mosquitoes, specifically in areas where people haven’t been vaccinated for yellow fever, can create small-scale epidemics. The WHO estimates that 50% of people who develop severe symptoms of this condition die. Older adults and those with compromised immune systems are at a risk for serious complications. The common symptoms of yellow fever include headache, nausea, fever, and vomiting. In severe cases, yellow fever affects some key organs such as the heart, kidney, and liver.
Market Dynamics
The increasing research and studies on yellow fever are expected to drive the global yellow fever treatment market growth during the forecast period. For instance, the Epicentre study, in collaboration with the Kenya Medical Research Institute, Institut Pasteur de Dakar, and WHO, carried out a randomized, double-blind trial in Mbarara, Kenya, Kilifi, and Uganda. The trial was carried out between November 6, 2017 and February 21, 2018. During this period, researchers administered one-fifth of a standard dose of yellow fever vaccine to about 960 adults between the ages of 18 and 59 years. In this study, it was found that giving people just one-fifth of a yellow fever vaccine was as effective as giving them a full dose. This means that more lives can be saved during outbreaks of the deadly disease. This study was led by Epicentre, the research arm of Médecins Sans Frontières / Doctors without Borders (MSF).
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients